MedTrace Logo

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00009906 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 748

Last updated 2014-12-23

No results posted yet for this study

Summary

Randomized phase III trial to compare the effectiveness of two different doses of STI571 in treating patients who have metastatic or unresectable gastrointestinal stromal tumor. STI571 may interfere with the growth of tumor cells and may be an effective treatment for cancer. It is not yet known which dose of STI571 is more effective in treating gastrointestinal stromal tumors.

Conditions

  • Gastrointestinal Stromal Tumor

Interventions

DRUG

Imatinib Mesylate

Given orally

Sponsors & Collaborators

  • Eastern Cooperative Oncology Group

    collaborator NETWORK

  • SWOG Cancer Research Network

    collaborator NETWORK

  • NCIC Clinical Trials Group

    collaborator NETWORK

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • George Demetri · SWOG Cancer Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Primary Completion
2007-05-31
Completion
2014-11-30

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00009906 on ClinicalTrials.gov